Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy

Johanna K. Björk1, Ilmari Ahonen2, Tuomas Mirtti3,4,5, Andrew Erickson4,5, Antti Rannikko6, Anna Bützow3, Stig Nordling3, Johan Lundin4, Mikael Lundin4, Lea Sistonen7,8, Matthias Nees1, and Malin Åkerfelt1,*

1Institute of Biomedicine, University of Turku, Turku, Finland
2Department of Mathematics and Statistics, University of Turku, Turku, Finland
3Department of Pathology, Medicum, University of Helsinki, Helsinki, Finland
4Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
5Department of Pathology, HUSLAB, Helsinki University Hospital, Helsinki, Finland
6Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
7Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland
8Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland

*These authors contributed equally to this work

Correspondence to: Malin Åkerfelt, email: malin.akerfelt@utu.fi

Keywords: biomarker; heat shock factor; predictive marker; prostate cancer; tissue microarray (TMA)

Received: March 09, 2018 Accepted: June 25, 2018 Published: July 27, 2018

Copyright: Björk et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Prostate cancer is a highly heterogeneous disease and the clinical outcome is varying. While current prognostic tools are regarded insufficient, there is a critical need for markers that would aid prognostication and patient risk-stratification. Heat shock transcription factor 1 (HSF1) is crucial for cellular homeostasis, but also a driver of oncogenesis. The clinical relevance of HSF1 in prostate cancer is, however, unknown. Here, we identified HSF1 as a potential biomarker in mRNA expression datasets on prostate cancer. Clinical validation was performed on tissue microarrays from independent cohorts: one constructed from radical prostatectomies from 478 patients with long term follow-up, and another comprising of regionally advanced to distant metastatic samples. Associations with clinical variables and disease outcomes were investigated. Increased nuclear HSF1 expression correlated with disease advancement and aggressiveness and was, independently from established clinicopathological variables, predictive of both early initiation of secondary therapy and poor disease-specific survival. In a joint model with the clinical Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score, nuclear HSF1 remained a predictive factor of shortened disease-specific survival. The results suggest that nuclear HSF1 expression could serve as a novel prognostic marker for patient risk-stratification on disease progression and survival after radical prostatectomy.

INTRODUCTION

Prostate cancer is one of the most commonly diagnosed male cancer in Western countries, and worldwide approximately one million new prostate cancer cases are diagnosed each year [1]. The clinical course is highly variable; although primary prostate cancer often remains indolent, a considerable proportion progresses into castration-resistant prostate cancer. Advanced prostate cancer can rapidly metastasize both locally to the lymph
nodes and distantly to bone, central nervous system, lung or other organs, and at this stage, despite therapeutic advances, there are still no curative treatments available and the metastasizing phenotype is lethal.

For localized prostate cancer a common treatment is radical prostatectomy. The most widely used tool to evaluate prognosis after primary treatment is Gleason grading, which is based on the glandular pattern of the tumor. However, accurate risk-stratification throughout the whole range of patients remains difficult, particularly for intermediate Gleason score tumors that often represent the vast majority of patients [2–4]. In addition, tumors with similar histological patterns can exhibit different clinical outcomes [5, 6]. Although Gleason grading was recently updated to a grade group system [7], and is being used in combination with other established parameters, foremost tumor stage and prostate-specific antigen (PSA), current prognostication is insufficient and accurate risk-stratification remains difficult. Additional information that allows more detailed and precise stratification of patients into distinct prognostic groups would be valuable. Thus, novel biomarkers for reliably assessing individual patient’s risk of disease progression and outcome are highly needed.

Heat shock factor 1 (HSF1) is a ubiquitously expressed transcription factor that is crucial for cellular homeostasis and protection against protein damaging stress via the evolutionary conserved heat shock response. HSF1 also plays a vital role in tumor biology e.g. by promoting proliferation and survival upon oncogenic stimuli. Absence of HSF1 reduces proliferation and survival of human cancer cell lines, and protects mice from mutation- or carcinogen-driven tumors [8–13]. The tumorigenic property of HSF1 stems from activation of distinct transcriptional programs, including oncogenic support processes such as cell-cycle regulation, metabolism, adhesion, and translation, in both cancer cells and the tumor stroma. This demonstrates both cell-autonomous and non-cell-autonomous capabilities of HSF1 in orchestrating malignancy [14, 15]. Clinical relevance for HSF1 was demonstrated in breast, lung, and hepatocellular carcinoma where high mRNA and/or protein expression correlates with poor prognosis [14–18]. Although we have demonstrated that HSF1 promotes invasion in prostate cancer cell lines [19] and elevated expression has been detected in cancer cell lines and tumors [14, 19, 20], evidence for clinical significance of HSF1 in prostate cancer has not been demonstrated.

Here, we explore the prognostic value of HSF1 in prostate cancer by analyzing independent mRNA gene expression datasets and two separate, large prostate cancer patient tissue microarray (TMA) cohorts: one radical prostatectomy cohort with extensive clinical information and long term follow-up (15.7 years) and a second separate cohort comprising of regionally advanced to distant metastatic tumors. Associations with clinical variables and disease outcomes were investigated using proportional hazards regression (univariate, multivariate and LASSO-penalized Cox), binary decision tree model, Kaplan–Meier estimates, and log-rank tests. We hypothesized that the expression status of HSF1 may be associated with progression and aggressiveness of prostate cancer and that HSF1 can be utilized for outcome prognostications of patients who have undergone radical prostatectomy.

RESULTS

HSF1 mRNA is overexpressed in prostate cancer

Since HSF1 has been demonstrated to be a strong promoter of oncogenesis, we hypothesized that HSF1 would hold clinical significance in prostate cancer. Previously, we have noted elevated levels of HSF1 mRNA when comparing human luminal prostate cancer cell lines to basal, benign prostate epithelial cell lines [19]. Thus, we first performed a large-scale analysis of HSF1 mRNA expression using all clinical prostate cancer datasets in cBioPortal (http://www.cbioportal.org/public-portal) [21, 22] available at the time of analysis. This revealed high expression of HSF1 mRNA in tumor samples across all datasets when compared to matched normal samples (Figure 1A) [23–29]. In-depth analyses on the transcriptomics dataset from MSKCC [23], containing comprehensive prostate cancer profiles of 216 clinical samples from both primary tumors and metastases were then performed. Statistically significantly elevated HSF1 levels were found to be associated with high grade group prostate cancer, positive lymph node status and metastasis (Figure 1B), all signs of progressing disease. Next, the association between mRNA expression and biochemical recurrence (BCR) was analyzed by stratifying the patients into high versus low HSF1 expressing groups. Interestingly, high HSF1 mRNA levels were associated with poor BCR-free patient survival ($p = 0.017$; Figure 1C). These results imply clinical significance for HSF1 in advanced prostate cancer, and justify an in-depth analysis of HSF1 protein expression in large prostate cancer cohorts.

Increased HSF1 protein expression corresponds to advancement of prostate cancer

We pursued the clinical relevance of differential expression of HSF1 by immunohistochemistry (IHC) [30] on a large primary prostate cancer cohort of radical prostatectomy samples, collected into TMA I (Supplementary Table 1) [31, 32]. In the final analysis, 368 patients had comprehensive clinical data and representative tissues in the TMA for analysis of HSF1. From each patient, three cores were obtained from the cancer areas and one core from an adjacent benign/normal area. HSF1 was mainly detected in the nucleus, and the signal was scored as negative, weak, intermediate, or strong (score 1–4, respectively; Figure 2A; Supplementary Figure 1).
Intriguingly, a clear majority (83%) of the prostate cancer cores showed intermediate to strong HSF1 expression, while 70% of the benign cores showed negative or weak HSF1 expression (Figure 2B). The association between HSF1 staining intensities and commonly used clinicopathological variables was further investigated by cross-tabulation and summary statistics (Table 1). This revealed that enhanced nuclear HSF1 expression was significantly associated with higher grade groups ($p = 0.014$), positive lymph node status ($p = 0.017$), and locally advanced (≥pT3) compared to organ-confined (pT2) disease ($p = 0.003$) (Figure 2C and 2D; Table 1). These results are in agreement with the increased HSF1 mRNA levels detected in advanced prostate cancer and local metastases (Figure 1B).

Interestingly, in approximately 20% of the prostate cancer samples with HSF1 expression status, HSF1 was also detected in the cytoplasm, where it was scored as negative (no staining) or positive (Figure 2E; Supplementary Table 1; Supplementary Figure 2). The incidence of positive cytoplasmic staining increased with higher nuclear HSF1 expression score and grade group (Figure 2F–2G).

**Strong HSF1 expression predicts risk of receiving secondary therapy**

We assessed the connection between HSF1 expression status and the likelihood of receiving secondary therapy after radical prostatectomy. Treatment decisions

---

**Figure 1: Analysis of HSF1 mRNA in large-scale transcriptomics datasets.** (A) Expression status of HSF1 in all publicly available clinical prostate cancer studies containing mRNA expression data in the cBioPortal (http://www.cbioportal.org) shown as percentages of samples with altered mRNA expression in the respective study. $z$-score ± 2. Numbers in parentheses refer to the respective reference. TCGA, provisional: data generated by the TCGA Research Network: http://cancergenome.nih.gov/. (B) Analysis of HSF1 mRNA expression in a clinical prostate cancer dataset comprising of 216 samples [23] showing that HSF1 expression is significantly increased in metastases, advanced prostate cancer (grade group 5), and lymph node invasion. The black line represents the median. Statistical significance was calculated using Mann-Whitney test. *$P$-values < 0.05; **$P$-values < 0.001. SM: positive surgical margins; SV inv: seminal vesicle invasion. (C) Kaplan–Meier estimates of biochemical recurrence (BCR)-free survival in HSF1 mRNA expression groups, comparing 25% low-level expressing versus 75% high-level expressing prostate cancer tumors in the MSKCC dataset [23].
Figure 2: Increased HSF1 protein expression corresponds to the progression of prostate cancer. (A) IHC staining of nuclear HSF1 protein on TMAs containing Gleason grade pattern 3–5 cores. Representative images are shown for negative (score 1), weak (score 2), intermediate (score 3), and strong (score 4) HSF1 expression. Scale bar represents 100 µm. Blow-up images in the insets. GL, Gleason grade. (B) Nuclear HSF1 protein staining status (negative, weak, intermediate, strong) in benign/normal and malignant prostate cancer biopsies. (C) Association between nuclear HSF1 protein staining status and grade group (GG), demonstrating that increased expression correlates with high grade group tumors. (D) Comparison of samples from local (pT2) and locally advanced (≥pT3) disease showing statistically significantly higher levels of nuclear HSF1 in tumors that have spread outside the prostate. (E) IHC staining on TMAs, showing representative images with both nuclear and cytoplasmic positive HSF1 expression (left) and with positive nuclear expression but negative cytoplasmic HSF1 expression (right). Scale bar represents 100 µm. Blow-up images in the insets. (F) Cross-tabulation of nuclear and cytoplasmic HSF1 protein expression. N = number of patients. (G) Association between cytoplasmic HSF1 protein staining status and GG.
for the patients were made by practicing urologists and reflect the clinical practice at the time. Analysis of the Kaplan–Meier estimates showed that strong nuclear HSF1 staining (score 4) was associated with shorter secondary therapy-free survival compared to low nuclear HSF1 staining (score 1–3) (Figure 3A, \(p = 0.033\)). Next, a univariate Cox regression model showed that strong nuclear HSF1 staining raised the risk of receiving secondary therapy with a hazard ratio (HR) of 1.56 (95% CI 1.03–2.35; \(p = 0.035\)) (Supplementary Table 2). When assessing the relationship between HSF1 and established clinical markers, a correlation matrix showed no marked dependencies (Supplementary Figure 3). In a multivariate Cox analysis that took established clinical markers into account, nuclear HSF1 staining remained an independent predictor of secondary therapy (HR 1.77; 95% CI 1.03–3.02; \(p = 0.037\)) (Supplementary Table 2).

Enhanced HSF1 expression correlates with poor disease-specific survival

Next, we studied the relationship between HSF1 expression and prostate cancer survival. In order to assess the utility of HSF1 as a prognostic marker further a competing risk analysis was performed where the probability to die specifically from prostate cancer, to die from other reasons, or to stay alive were compared in relation to the expression status of nuclear HSF1 (Figure 3B). Interestingly, strong nuclear HSF1 expression clearly increased the likelihood to die from the disease (HR 2.55; 95% CI 1.10–5.94; \(p = 0.029\)). No evidence was found for HSF1 affecting the probability of dying for other reasons. To investigate the prognostic value of HSF1 in different patient groups and in relation to grade group on disease-specific survival, a survival decision tree was generated (Supplementary Figure 4A). The individual nuclear and cytoplasmic HSF1 scores as well as grade group were supplied as factors to the algorithm after which no further user interaction was required. Survival up to given time points in the patient groups derived by the tree is illustrated in Supplementary Figure 4B. The resulting tree revealed that while grade group remained the most informative prognostic factor (node 1), nuclear HSF1 expression status added to the survival prediction for advanced cancers (node 5; Supplementary Figure 4A). Simultaneously, the decision tree confirmed the division of nuclear HSF1 status used in analyses above, i.e. low (scores 1–3) vs strong (score 4) expression, as the most informative cut point (node 5). Cytoplasmic HSF1 enhanced the prognostic value when the grade group was low (≤ 2; node 2).

Table 1: Association between the level of nuclear and cytoplasmic HSF1 expression and tumor characteristics in TMA I

| Tumor characteristics | Nuclear HSF1 score | Cytoplasmic HSF1 score |
|------------------------|---------------------|------------------------|
|                        | 1–3 | 4 | \(P^a\) | Negative | Positive | \(P^b\) |
|                        | \(n (%)\) | \(n (%)\) | \(n (%)\) | \(n (%)\) | \(n (%)\) | \(n (%)\) |
| Grade group (Gleason score) | 1 (4–6) | 41 (58.6) | 29 (41.4) | 0.033 | 56 (81.2) | 13 (18.8) | 0.050 |
|                        | 2 (3 + 4 = 7) | 50 (57.5) | 37 (42.5) | | 77 (86.5) | 12 (13.5) | |
|                        | 3 (4 + 3 = 7) | 52 (46.4) | 60 (53.6) | | 85 (75.9) | 27 (24.1) | |
|                        | 4 (8) | 14 (32.6) | 29 (67.4) | | 27 (64.3) | 15 (35.7) | |
|                        | 5 (9–10) | 5 (38.5) | 8 (61.5) | | 10 (71.4) | 4 (28.6) | |
| pT                        | 2 | 101 (57.7) | 74 (42.3) | 0.003 | 143 (81.7) | 33 (18.3) | 0.16 |
|                        | ≥3 | 55 (43.7) | 71 (56.3) | | 95 (74.8) | 32 (25.2) | |
| Positive surgical margin | Yes | 29 (51.8) | 27 (48.2) | 1.00 | 50 (86.2) | 8 (13.8) | 0.12 |
|                        | No | 143 (50.9) | 138 (49.1) | | 213 (76.1) | 67 (23.9) | |
| Lymph node status Benign | 172 (52.6) | 155 (47.4) | | 0.017 | 258 (78.7) | 70 (21.3) | 1.00 |
| Metastasis | 1 (11.1) | 8 (88.9) | | | 7 (77.8) | 2 (22.2) | |
| PSA µg/L\(b\) (SD) | 15.3 (±14.7) | 13.5 (±12.3) | 0.13 | 15.0 (±14.2) | 12.1 (±10.7) | 0.047 |

\(p\)-values are calculated using the Fisher’s exact test for categorical variables and Wilcoxon test for continuous variables.

\(b\) PSA is preoperative and values are mean.

Abbreviations: SD, standard deviation; PSA, prostate-specific antigen.
death (\(p = 0.012\); Figure 3C). At 10 years post-operation the likelihood of disease-specific survival was decreased by 8.4% (95% CI 2.8–14.0; Figure 3C). Disease-specific survival was not statistically significantly affected when stratifying patients by cytoplasmic HSF1 staining (Figure 3D). When combining nuclear and cytoplasmic HSF1 staining, patients with low nuclear expression (score 1–3) and negative cytoplasmic HSF1 showed the lowest disease-specific survival time compared to the other groups (Figure 3E). Cytoplasmic HSF1 also added to the prognostic value of the low-risk group with nuclear HSF1 score 1–3 (Figure 3E, \(p = 0.023\)).

HSF1 is a prognostic marker for prostate cancer-specific death

For prostate cancer-specific death, a univariate Cox proportional hazards model showed that strong nuclear HSF1 staining raised the risk with a HR of 2.62 (95% CI 1.21–5.67; \(p = 0.015\); Table 2). When incorporating nuclear HSF1 together with grade group alone in a multivariate model, strong nuclear HSF1 remained an independent factor with a HR of 2.40 (95% CI 1.06–5.41; \(p = 0.035\); Table 2). This should be compared to the HR of GG, which was 1.78 (95% CI 1.28–2.48; \(p = 0.001\)). Possibly due to the small number of events (4.9% of the patients were deceased due to prostate cancer), the association with disease-specific survival did not reach statistical significance if additional variables were included into the model (Supplementary Table 3).

To widen the range of clinical variables examined together with HSF1, we utilized the least absolute shrinkage and selection operator (LASSO)-regression model in combination with multiple imputation to account for missing values in the covariates. Four variables; \(pT \geq 3\), metastatic lymph node status, grade group 3 and 4–5, and strong HSF1 nuclear staining (score 4) were independently chosen by LASSO in over 75% of the imputed datasets suggesting that these hold independent prognostic value for disease-specific survival (Figure 3F). Further investigations on HSF1’s performance were assessed by the full clinical model CAPRA-S, which includes the variables PSA, GS in the radical prostatectomy specimen, surgical margin, seminal vesicle invasion, extracapsular extension, and lymph node invasion [33]. After demonstrating non-dependency between HSF1 and CAPRA-S in an analysis of variance in which the average CAPRA-S scores did not differ statistically significantly between the nuclear HSF1 groups (\(F\)-test \(p = 0.221\)), multivariable analysis combined with multiple imputation was performed. This revealed a HR of 2.27 (95% CI 1.04–4.98) for a combined model with nuclear HSF1 and HR 1.27 (95% CI 1.11–1.46) for CAPRA-S (Table 2). The average \(p\)-value from the imputed datasets in a subsequent likelihood-ratio test comparing the joint model and the CAPRA-S score alone was 0.032, indicating that HSF1 brings added prognostic value on top of the CAPRA-S score. Taken together the results demonstrate that nuclear HSF1 is an independent prognostic marker from the currently established variables for guiding treatment decisions, and could potentially be used in clinical practice.

HSF1 is excessively expressed in advanced and metastatic tumors

Finally, to verify HSF1 stainings on TMAs and since HSF1 levels, both mRNA and protein, were found to increase with prostate cancer progression (Figure 1B; Figure 2C; Table 1), we performed IHC on a large cohort from advanced prostate cancers (TMA II). This independent TMA contained 103 cores from the seminal vesicles and from metastases in the abdominal space, bladder, bone and local lymph nodes from 57 patients. Representative images from the seminal vesicles and metastatic sites showed HSF1 expression in infiltrating tumor cells (Figure 4A). Strikingly, intermediate or strong HSF1 nuclear expression was detected in the vast majority (93%) of the advanced cancer cores, and all except one of the cores simultaneously showed positive cytoplasmic HSF1 staining (Figure 4B–4C). The excessive amounts of both nuclear and cytoplasmic HSF1, independently of the metastatic site, highlight HSF1 as a key factor in invasion and metastasis of prostate cancer.

DISCUSSION

HSF1 is foremost known for mediating the heat shock response, a highly conserved mechanism that protects the cell from environmental and pathological proteotoxic damage [34]. In cancer, proteotoxic stress arises from various sources such as the heightened degree of aneuploidy, accumulation of mutated proteins and the harsh conditions of the tumor microenvironment [35, 36]. Not surprisingly, HSF1 expression has been found to be elevated in various cancer cell lines and cancer types and HSF1 identified as a driver of carcinogenesis [8, 10, 11]. It appears that cancer cells may hijack HSF1 functions and its transcriptional activity to promote survival, growth and metastatic propensity [13, 14]. While the oncogenic potential of HSF1 has been thoroughly demonstrated on a molecular level, its clinical significance has only begun to be revealed [14, 16]. We recently demonstrated that the absence of HSF1 renders prostate cancer cell lines in a non-differentiating acinar state, non-invasive, and prone to cell death in 3D organotypic cell culture. Likewise, in the chorioallantoic membrane in vivo model, tumors derived from prostate cancer cell lines showed reduced growth upon knock-down of HSF1 expression [19]. In this study a clinical significance of HSF1 in prostate cancer is demonstrated: increased HSF1 expression associates with disease progression and independently predicts initiation...
of secondary therapy and poor disease-specific survival of prostate cancer patients after radical prostatectomy. This suggests that HSF1 could serve as a novel prognostic marker in prostate cancer.

The prognostic value of HSF1 was here demonstrated using a comprehensive radical prostatectomy cohort with extensive follow-up time necessary for clinically relevant end points: initiation of secondary treatment and

![Figure 3: Elevated HSF1 expression predicts shorter time to secondary therapy and poorer disease-specific survival after radical prostatectomy.](image)

(A) Kaplan–Meier estimates of time to secondary therapy after radical prostatectomy showing low (score 1–3) versus strong (score 4) nuclear HSF1 staining, (B) Competing risk analysis where the probability to be in a specific state; alive (green), dead due to prostate cancer (red), and dead due to other reasons (blue), were estimated in relation to nuclear HSF1 expression, i.e. strong (score 4) versus low (score 1–3). (C–E) Kaplan–Meier estimates of disease-specific survival showing (C) strong (4) versus low (1–3) nuclear HSF1 staining, (D), negative or positive cytoplasmic HSF1 staining, or (E) combinations of nuclear and cytoplasmic HSF1 staining. (F) Variables chosen by the LASSO-regression model combined with multiple imputation and with disease-specific survival as the end point. The covariates were tumor extension (pT), lymph node status, log preoperative PSA, GG, nuclear HSF1 staining, cytoplasmic HSF1 staining, and age at operation. Bright green indicates prognostic value; bright red indicates equivocal prognostic value; shades of grey indicate that no conclusions can be drawn from these data. N = number of patients.
disease-specific survival. TMA I revealed that increased nuclear HSF1 expression is evident in malignant tissues and correlates with disease progression. Another independent TMA (TMA II), composed of prostate cancer in seminal vesicles or metastases, as well as the mining of publicly available mRNA datasets verified our findings of increased expression during disease advancement. In accordance, enhanced HSF1 mRNA expression has been detected in breast and hepatocellular carcinoma and enhanced nuclear HSF1 protein expression in a wide range of malignancies including hepatocellular carcinoma, breast, cervical, lung, pancreas, colon, and mesenchymal tumors [14, 16–18].

The clinical course of prostate cancer is highly variable and more accurate risk-stratification of patients is needed for informed therapeutic decision-making. One particular problem is the selection of individuals that are likely to benefit from locoregional and systemic treatment following radical prostatectomy of intermediate and high-risk patients. Despite extensive research to uncover reliable biomarkers that provide improved sensitivity over current tools, only three biomarkers are currently approved for clinical use by the US Food and Drug Administration (FDA): PSA, the related prostate health index that combines different PSA forms, and prostate cancer antigen 3 (PCA3), a long non-coding RNA. A number of additional biomarkers, such as TMPRSS2-ERG gene fusion test and tests containing panels of markers, are offered as Clinical Laboratory Improvement Amendments-based laboratory developed tests. However, none of these has of yet been approved by the US FDA for clinical practice [37]. This study suggests that HSF1 is a driver of prostate cancer progression and could serve as an informative biomarker for stratifying patients after radical prostatectomy. Strong nuclear HSF1 expression was, independently from established clinicopathological markers, associated with shorter time to secondary therapy. Importantly, strong nuclear HSF1 expression also predicted poor disease-specific survival, demonstrating HSF1 as a determinant of lethal disease. Of note, the prognostic HR values derived from HSF1 nuclear scores were comparable to those derived from common established clinical markers such as GG. In addition, independence from the full clinical model CAPRA-S, as demonstrated by variance analysis, allowed a combined risk analysis after multiple imputation. Subsequent likelihood-ratio test demonstrated the value of nuclear HSF1 in the model for predicting disease-specific survival.

Although the size and follow-up time of the patient cohorts used in this study were substantial and enabled pertinent end point analyses, the relatively low count of lethal events reduced the statistical power in subgroup and multivariate models. For these reasons, a multivariate Cox analysis of disease-specific survival was of only limited use. However, by utilizing LASSO-penalization and applying multiple imputation, these shortages were addressed and the prognostic value of HSF1 shown. Specifically, the joint analysis with the established CAPRA-S score with subsequent likelihood-ratio test verified HSF1 as an independent and relevant marker. Prospective studies on extensive, independent cohorts are however warranted to estimate the magnitude of the effect.

This study is based on samples taken after radical prostatectomy or at an advanced stage. For subsequent

| Univariate | HR   | 95% CI | P     |
|------------|------|--------|-------|
| HSF1 nuclear (score 4 vs 1–3) | 2.62 | 1.21–5.67 | 0.015 |
| HSF1 cytoplasmic (positive vs negative) | 1.91 | 0.90–4.04 | 0.091 |
| Grade group | 1.88 | 1.38–2.56 | <0.001 |
| pT (≥T3 vs T2) | 12.85 | 3.86–42.82 | <0.001 |
| PSA | 1.03 | 1.01–1.05 | 0.011 |
| Positive surgical margin | 0.62 | 0.22–1.77 | 0.37 |
| Lymph node metastasis | 5.05 | 1.75–14.55 | <0.001 |

**Multivariate**

| HR   | 95% CI | P     |
|------|--------|-------|
| HSF1 nuclear (score 4 vs 1–3) | 2.40 | 1.06–5.41 | 0.035 |
| Grade group | 1.78 | 1.28–2.48 | 0.001 |

**Multivariate + MI**

| HR   | 95% CI | P     |
|------|--------|-------|
| CAPRA-S | 1.27 | 1.11–1.46 |       |
| HSF1 nuclear | 2.27 | 1.04–4.98 |       |

*Number of patients, 324; number of events, 31.
Abbreviations: CI, confidence interval; HR, hazard ratio; MI, multiple imputation.
IHC analyses, HSF1 status could be surveyed in biopsies and connected to disease outcome for a prognostic value on progression and disease-specific survival, possibly saving patients from unnecessary radical prostatectomy and aiding earlier treatment. Although IHC is an indispensable technique in pathology laboratories, varying staining quality can pose a problem. However, potential problems can be overcome by following published guidelines on standardization [38, 39]. These include the use of an antigen retrieval method that enables detection from formalin-fixed and paraffin-embedded surgical specimens, automated staining, and digital pathology combined with imaging analysis. Furthermore, thorough antibody testing, optimization, and validation, including the use of positive and negative controls, is a prerequisite. In order to use HSF1 IHC analyses as an established method in clinics in the future, a standard operating procedure protocol should be developed.

Apart from the prognostic value, our findings hold therapeutic potential. HSF1 has been considered a target for anti-cancer therapy due to the dependency of malignancies on this non-oncogene and its overexpression in many cancers [40]. Several small molecular inhibitors of HSF1 have been identified [40, 41], and a water-soluble pro-drug of the inhibitor triptolide is currently in phase I clinical trial for advanced gastrointestinal tumors (NTCT01927965) and has demonstrated pre-clinical activity against hepatocellular carcinoma, osteosarcoma, and ovarian and pancreatic cancer [42–44]. Our results on differential expression of HSF1 open up for therapeutic interventions also in prostate cancer.

In conclusion, this study enhances the understanding of prostate cancer progression by demonstrating that the levels of HSF1 increases as the disease advances and that HSF1 status predicts disease-specific survival. Taken together, the study demonstrates that characterizing HSF1 expression with straightforward and robust antibody-based detection holds potential for use in clinical practice, i.e. for risk-stratification and outcome predictions of patients treated with radical prostatectomy.

MATERIALS AND METHODS

Study design

Reporting recommendations for tumor marker prognostic studies; REMARK [45] was followed throughout the study. The study design is outlined in Supplementary Figure 5.

Bioinformatics of mRNA expression in clinical samples

Expression status of HSF1 was investigated in all clinical prostate cancer studies available at the time of analysis through the cBioPortal for Cancer Genomics.

Figure 4: HSF1 protein expression in samples from regionally advanced to distant metastatic sites of prostate cancer. (A) IHC stainings of HSF1 on TMA II containing samples from the abdominal space (Ab), bladder (Bl), bone (Bo), iliac lymph node (LN), and seminal vesicle (SV). Scale bar represents 100 µm. Blow-ups in the insets. (B) Distribution of nuclear HSF1 intensity at the different sites. (C) Cross-tabulation of the level of nuclear and cytoplasmic HSF1 expression in the samples. (B–C) The numbers designate patients.
Clinical prostate cancer samples for tissue microarrays

Prostate cancer specimens from two independent clinical cohorts were constructed into TMA I and II. For TMA I, samples were obtained from 478 patients treated by radical prostatectomy during the years 1982–1998 at Helsinki University Hospital, Finland. For the final analysis, 368 patients without neoadjuvant treatment and with comprehensive data, HSF1 expression status, and tissue material available were included. Clinical preoperative and follow-up information including overall and disease-specific mortality data was gathered from the Finnish Cancer Registry, and updated in November 2015. The age of the patients at diagnosis ranged between 45 and 76 years, and none had received adjuvant therapy before or immediately after surgery. The median post-surgery follow-up time was 15.7 years (Supplementary Table 1). For TMA II, 103 samples from regionally advanced and distant metastatic sites of 62 patients treated at Turku University Hospital, Finland between 1993 and 2008, were used [47]. In the final analysis, cores from 57 samples were representative for scoring, including 1 abdominal, 2 bladder, 7 bone, 31 lymph node metastases and 16 seminal vesicle infiltration samples. The median age of the patients was 64 years, and some had received hormonal treatments. For both TMAs, histopathological features were independently reviewed by pathologists using hematoxylin-eosin or Herovici’s collagen stained slides. Sample and clinicopathological data usage was approved by the ethics committees of Hospital District of Helsinki and Uusimaa and Hospital District of Southwest Finland, and the National Authority for Welfare and Health in Finland according to national legislation. Use of the Finnish Cancer Registry’s data was approved by the National Institute for Health and Welfare. Patient data was de-identified prior to analyses.

Construction of the TMAs and immunohistochemistry

The TMAs were constructed using archival formalin-fixed, paraffin-embedded blocks as described in [32]. For TMA I, the blocks from each patient were drilled from different areas to account for tumor heterogeneity: two cores from the area containing the most dominant Gleason grade pattern, one core form the area containing the second most dominant Gleason pattern, and one core from an adjacent benign glandular area. TMA I, comprising prostate cancer prostatectomy samples, contained a total of 1758 cores. TMA II, comprising disseminated prostate cancer samples, contained a total of 105 cores from regional and distant sites. All cancer cores were scored individually, according to the Gleason grade pattern. Freshly cut 4 μM thick TMA sections were mounted on electrically charged glass slides (SuperFrost Plus, Menzel-Gläser, Germany), and stained using Lab Vision™ PT Module and Autostainer 480 (Thermo Scientific, Waltham, MA, USA) with heat-induced epitope retrieval in TRIS buffer. The slides were incubated with rabbit polyclonal HSF1 antiserum (1:1000), generated and described previously [30]. Shortly, purified 65–70 kDa recombinant human HSF1 was used for immunization of rabbits. Specificity was verified by Western blotting using recombinant human HSF1 and human cell lysates [30]. For the TMA, HSF1 staining of normal, human urinary bladder tissue was used as a positive control, showing consistency with stainings in Protein Atlas (https://www.proteinatlas.org/ENSG00000185122-HSF1/tissue). Rabbit IgG staining of prostate cancer tissue was used as a negative antibody control (Supplementary Figure 1).

Digitalization and scoring of TMA cores

The TMAs were analyzed largely as described by Björkman et al., 2012 [32]. The immunostained TMA sections were digitized with an automated whole slide scanner (Mirax Scan, Zeiss, Germany) and virtual slides were uploaded to a web server (http://fimm.webmicroscope.net). Reliable Gleason grading was possible for 1064 out of 1104 prostate cancer TMA I cores stained with HSF1 antibody. HSF1 expression was evaluated by a pathologist (TM) independently from the digitized slides without information on grade and clinicopathological data. In all analyses, the maximum HSF1 score of the available prostate cancer cores for each individual patient was used. The nuclear staining intensity was scored as: no staining (negative, score 1), weak (score 2), intermediate (score 3), or high (score 4), and the cytoplasmic staining was scored as: no staining (negative) or positive. To assess the reliability of the HSF1
measurements, the correlation structure of the scores was investigated (Supplementary Figure 6). In short, little or no dependency was found between scores from differing sources, while scores from the same source were moderately correlated (Spearman $r = 0.57–0.66$). This level of agreement can be considered satisfactory, however, low enough to justify multiple samples from each patient.

**Statistical analysis**

Associations between categorical variables were investigated by cross-tabulation and Fisher’s exact test. Differences in average values of continuous variables between factor groups were assessed with non-parametric Wilcoxon signed-rank test. Survival analyses were performed with Kaplan–Meier estimates and log-rank tests. HRs were obtained by fitting Cox proportional hazards regression models for single and multiple prognostic factors. Correlations between variables were estimated using the non-parametric Spearman’s rank correlation.

A binary decision tree [48] was utilized to provide an automated approach to deriving useful prognostic groups. In contrast to the Cox models using only the main effects of the variables, this approach makes minimal assumptions on the structure of the data and is able to detect possible interactions between covariates and nonlinear dependencies. The tree was constructed by consecutively splitting the patients into groups at points that minimize the log-rank test $p$-value. The splitting point is chosen among all covariates supplied to the algorithm. The method can thus also be used for identifying useful prognostic factors.

Least absolute shrinkage and selection operator (LASSO)-penalized Cox regression [49] was used for picking the most relevant variables among a large set of prognostic factors. The method aims to set the HR related to unnecessary prognostic factors to exactly 1, thus negating their effect in the model. The method is controlled by a hyperparameter $\lambda$, whose value was chosen using 5-fold cross-validation [50].

Multiple imputation [51] was used to address the missing values of variables other than HSF1 expression in the data. The method imputes any missing data with reasonable guesses by taking into account the (non-missing) values in the other variables. The guesses are random, and thus to characterize the full uncertainty in the missing value estimation, the procedure is repeated multiple times. This results in a set of imputed datasets that differ in their imputed missing values. The subsequent analyses are then performed on each of the datasets and the results are combined for the final analysis using Rubin’s rules [52].

Multivariate analyses with Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score were performed as detailed in [33]. In an analysis of variance, the average CAPRA-S scores did not differ statistically significantly between the nuclear HSF1 groups ($F$ test $p = 0.221$) demonstrating non-dependency between HSF1 and CAPRA-S. Missing values in the data set were handled by multiple imputation, however no HSF1 data was imputed. 100 imputed datasets were created with varying imputed values reflecting the uncertainty of the imputation. The Cox model was fitted on each of the imputed datasets and collected into a single analysis. The variation between the imputed datasets was significantly smaller than the average estimation uncertainty for disease-specific survival (Supplementary Table 4). From these data, confidence intervals for the HRs were constructed using Rubin’s rules.

All statistical analyses were performed with the programming language R, version 3.2 (R Foundation for Statistical Computing, http://www.R-project.org). Nonstandard external R-packages used include glmnet [53], ggplot2 [54], mi [55], riskRegression (https://CRAN.R-project.org/package=riskRegression) and rpart (https://CRAN.R-project.org/package=rpart).

**Abbreviations**

BCR: biochemical recurrence; CAPRA-S: Cancer of the Prostate Risk Assessment post-Surgical; GG: grade group; GL: Gleason grade; HSF1: heat shock factor 1; HR: hazard ratio; IHC: immunohistochemistry; LASSO: least absolute shrinkage and selection operator; PSA: prostate-specific antigen; TMA: tissue microarray.

**Author contributions**

Conception and design of the experiments: JKB, MÅ, MN, TM. Acquisition of data: AB, SN, TM. Analysis and interpretation of data: IA, JKB, MÅ, TM. Statistical analysis: IA. Writing of the manuscript: JKB. Administrative, technical, or material support: AB, AE, AR, JL, LS, ML, MN, SN, TM. All authors have reviewed and validated the manuscript.

**ACKNOWLEDGMENTS**

Paula Vainio is acknowledged for valuable help in data collection (TMA II) and Tiina Vesterinen for IHC stainings.

**CONFLICTS OF INTEREST**

The authors declare that they have no conflicts of interest.

**FUNDING**

This work was supported by the Academy of Finland (265918 (JKB), 267326 (MN), 268531 (TM)),
Finnish Medical Foundation (TM) and Cancer Society Finland (TM). The authors confirm that the funder had no influence over the study design, content of the article, or selection of journal.

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–86.

2. Tefilli MV, Gheiler EL, Tiguert R, Sakr W, Grignon DJ, Banerjee M, Pontes JE, Wood DP Jr. Should Gleason score 7 prostate cancer be considered a unique grade category. Urology. 1999; 53:372–377.

3. Lau WK, Blute ML, Bostwick DG, Weaver AL, Sebo TJ, Zincke H. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol. 2001; 166:1692–1697.

4. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Egevad L, Amin MB, Delahunt B, Srigley JR, Zincke H. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol. 2012; 187:92–103.

5. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010; 24:1967–2000.

6. Schoenborn JR, Nelson P, Fang M. Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res. 2013; 19:4058–4066.

7. Epstein JI, Egevad L, Amin MB, Delahunt B, Stiglely JR, Humphreys PA; Grading Committee: The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016; 40:244–252.

8. Dai C, Whitesell L, Rogers AB, Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell. 2007; 130:1005–1018.

9. Min JN, Huang L, Zimonjic DB, Moskophidis D, Mivechi NF. Selective suppression of lymphomas by functional loss of HSF1 in a p53-deficient mouse model for spontaneous tumors. Oncogene. 2007; 26:5086–5097.

10. Jin X, Moskophidis D, Mivechi NF. Heat shock transcription factor 1 is a key determinant of HCC development by regulating hepatic steatosis and metabolic syndrome. Cell Metab. 2011; 14:91–103.

11. Scott KL, Nogueira C, Heffernan TP, van Doorn R, Dhakal S, Hanna JA, Min C, Jaskelioff M, Xiao Y, Wu CJ, Cameron LA, Perry SR, Zeid R, et al. Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell. 2011; 20:92–103.

12. Xi C, Hu Y, Buckhaults P, Moskophidis D, Mivechi NF. Heat Shock Factor Hsf1 Cooperates with ErbB2 (Her2/Neu) to Promote Mammary Tumorigenesis and Metastasis. J Biol Chem. 2012; 287:35646–35657.

13. Vihervaara A, Sistonen L. HSF1 at a glance. J Cell Sci. 2014; 127:261–266.

14. Mendillo ML, Santagata S, Koeva M, Bell GW, Hu R, Tamimi RM, Fraenkel E, Ince TA, Whitesell L, Lindquist S. HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers. Cell. 2012; 150:549–562.

15. Scherz-Shouval R, Santagata S, Mendillo ML, Sholl LM, Ben-Aharon I, Beck AH, Dias-Santagata D, Koeva M, Stemmer SM, Whitesell L, Lindquist S. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell. 2014; 158:564–578.

16. Santagata S, Hu R, Lin NU, Mendillo ML, Collins LC, Hankinson SE, Schnitt SJ, Whitesell L, Tamimi RM, Lindquist S, Ince TA. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A. 2011; 108:18378–18383.

17. Fang F, Chang R, Yang L. Heat shock factor 1 promotes invasion and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer. 2012; 118:1782–1794.

18. Gokmen-Polar Y, Badve S. Upregulation of HSF1 in estrogen receptor positive breast cancer. Oncotarget. 2016; 7:84239–84245. https://doi.org/10.18632/oncotarget.12438.

19. Björk JK, Åkerfelt M, Joutsen J, Puustinen MC, Cheng F, Sistonen L, Nees M. Heat-shock factor 2 is a suppressor of prostate cancer invasion. Oncogene. 2016; 35:1770–1784.

20. Hoang AT, Huang J, Rudra-Ganguly N, Zheng J, Powell WC, Rabindran SK, Wu C, Roy-Burman P. A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. Am J Pathol. 2000; 156:857–864.

21. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, et al. The eBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2:401–404.

22. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the eBioPortal. Sci Signal. 2013; 6:11.

23. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18:11–22.

24. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and...
MED12 mutations in prostate cancer. Nat Genet. 2012; 44:685–689.

25. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487:239–243.

26. Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015; 163:1011–1025.

27. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161:1215–1228.

28. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrt J, Marotz C, Giannopoulou E, Chakravartli BV, Varambally S, Tomlins SA, Nanan DM, Tagawa ST, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016; 22:298–305.

29. Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Eliziori R, Bolouri H, Montgomery B, White T, Lucas JM, Brown LG, Dumpit RF, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016; 22:369–378.

30. Holmberg CI, Illman SA, Kallio M, Mikhailov A, Sistonen L. Formation of nuclear HSF1 granules varies depending on stress stimuli. Cell Stress Chaperones. 2000; 5:219–228.

31. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Vesterinen T, Nordling S, Kallioniemi O, et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 2011; 30:3962–3976.

32. Björkman M, Östling P, Härmä V, Rannikko A, Kaivanto E, Kohonen P, et al. Systematic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biol. 2008; 9:R139.

33. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011; 117:5039–5046.

34. Åkerfelt M, Morimoto RI, Sistonen L. Heat shock factors: integrators of cell stress, development and lifespan. Nat Rev Mol Cell Biol. 2010; 11:545–555.

35. Solimini NL, Luo J, Elledge SJ. Non-oncogene addiction and the stress phenotype of cancer cells. Cell. 2007; 130:986–988.

36. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009; 136:823–837.

37. Saini S. PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol. 2016; 39:97–106.

38. Goldstein NS, Hewitt SM, Taylor CR, Yaziji H, Hicks DG; Members of Ad-Hoc Committee On Immunohistochemistry Standardization. Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol. 2007; 15:124–133.

39. Lin F, Chen Z. Standardization of diagnostic immunohistochemistry: literature review and geisinger experience. Arch Pathol Lab Med. 2014; 138:1564–1577.

40. Whitesell L, Lindquist S. Inhibiting the transcription factor HSF1 as an antitumor strategy. Expert Opin Ther Targets. 2009; 13:469–478.

41. Moore CL, Dewal MB, Nkengco EE, Santiago S, Lu NB, Levine SS, Shoulders MD. Transportable, Chemical Genetic Methodology for the Small Molecule-Mediated Inhibition of Heat Shock Factor 1. ACS Chem Biol. 2016; 11:200–210.

42. Westerheide SD, Kawahara TL, Orton K, Morimoto RI. Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem. 2006; 281:9616–9622.

43. Chugh R, Sangwan V, Patil SP, Dudeja V, Dawra RK, Banerjee S, Schumacher RJ, Blazar BR, Georg GI, Vickers SM, Saluja AK. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012; 4:156ra139.

44. Banerjee S, Thayanithy V, Sangwan V, Mackenzie TN, Saluja AK, Subramanian S. Minnelide reduces tumor burden in preclinical models of osteosarcoma. Cancer Lett. 2013; 335:412–420.

45. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005; 93:387–391.

46. Kilpivaara O, Johnsson S, Kallioniemi O, et al. Minnelide reduces tumor burden in preclinical models of osteosarcoma. Cancer Lett. 2009; 279:147–155.

47. Vainio P, Gupta S, Ketola K, Mirtti T, Mpindi JP, Kohonen P, et al. Systematic integration of cell stress, development and lifespan. Nat Rev Mol Cell Biol. 2010; 11:545–555.

48. Strobl C, Malley J, Tutz G. An introduction to recursive partitioning: rationale, application, and characteristics of
classification and regression trees, bagging, and random forests. Psychol Methods. 2009; 14:323–348.

49. Simon N, Friedman J, Hastie T, Tibshirani R. Regularization Paths for Cox’s Proportional Hazards Model via Coordinate Descent. J Stat Softw. 2011; 39:1–13.

50. Arlot S, Celisse A. A survey of cross-validation procedures for model selection. Statistics Surveys. 2010; 4:40–79.

51. Raghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger P. A Multivariate Technique for Multiply Imputing Missing Values Using a Sequence of Regression Models. Surv Methodol. 2001; 27:85–95.

52. Rubin D. Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons. New York. 1987.

53. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33:1–22.

54. Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag. New York. 2009.

55. Su Y, Gelman A, Hill J, Yajima M. Multiple Imputation with Diagnostics (mi) in R: Opening Windows into the Black Box. J Stat Softw. 2011; 45:1–31.